Skip to main content


Fig. 3 | Diabetology & Metabolic Syndrome

Fig. 3

From: Degludec: the new ultra-long insulin analogue

Fig. 3

Day-to-day variability in the glucose - lowering effect of insulin degludec (IDeg) and insulin glargine (IGlar) over 24 h at steady state as shown by the coefficient of variation (CV) for the pharmacodynamic endpoint (area under the curve for glucose infusion rates from 0–24 h). Adapted from Reference [13] (Heise et al.)

Back to article page